PLSE vs. NVRO, SKIN, OSUR, ANIK, BVS, SRDX, NPCE, LUNG, TCMD, and CERS
Should you be buying Pulse Biosciences stock or one of its competitors? The main competitors of Pulse Biosciences include Nevro (NVRO), Beauty Health (SKIN), OraSure Technologies (OSUR), Anika Therapeutics (ANIK), Bioventus (BVS), Surmodics (SRDX), NeuroPace (NPCE), Pulmonx (LUNG), Tactile Systems Technology (TCMD), and Cerus (CERS). These companies are all part of the "surgical & medical instruments" industry.
Nevro (NYSE:NVRO) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.
Nevro currently has a consensus price target of $20.00, suggesting a potential upside of 90.11%. Given Pulse Biosciences' higher probable upside, equities analysts plainly believe Nevro is more favorable than Pulse Biosciences.
In the previous week, Nevro had 11 more articles in the media than Pulse Biosciences. MarketBeat recorded 18 mentions for Nevro and 7 mentions for Pulse Biosciences. Nevro's average media sentiment score of 0.29 beat Pulse Biosciences' score of 0.20 indicating that Pulse Biosciences is being referred to more favorably in the news media.
Pulse Biosciences has a net margin of 0.00% compared to Pulse Biosciences' net margin of -21.69%. Pulse Biosciences' return on equity of -30.22% beat Nevro's return on equity.
Nevro has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500.
Nevro received 256 more outperform votes than Pulse Biosciences when rated by MarketBeat users. Likewise, 65.84% of users gave Nevro an outperform vote while only 65.17% of users gave Pulse Biosciences an outperform vote.
Pulse Biosciences has lower revenue, but higher earnings than Nevro. Pulse Biosciences is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks.
95.5% of Nevro shares are owned by institutional investors. Comparatively, 76.9% of Pulse Biosciences shares are owned by institutional investors. 3.2% of Nevro shares are owned by insiders. Comparatively, 71.5% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Nevro beats Pulse Biosciences on 10 of the 17 factors compared between the two stocks.
Get Pulse Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulse Biosciences Competitors List
Related Companies and Tools
